Related Experiment Video
Updated: Dec 1, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
[Product improvement and secondary development of Pudilan Xiaoyan Oral Liquid based on clinical medication]
Yang Dang1, Jiang Meng-Hua1, G U Hui-Min2
1School of Traditional Chinese Pharmacy,China Pharmaceutical University Nanjing 211198,China Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine Nanjing 210028,China.
Abstract:
Pudilan Xiaoyan Oral Liquid is widely used in clinical applications, with safe and effective results. Its coverage rate in the national first, second and third grade hospitals is as high as 71%. In this study, we analyzed and summarized the research progress on the material basis, quality control, production process and clinical medication of Pudilan Xiaoyan Oral Liquid based on the clinical diseases(parotitis, tonsillitis, pharyngitis), and deeply explored the intrinsic quality improvement and secondary development of Pudilan product. Pharmacodynamic material basis of Pudilan Xiaoyan Oral Liquid was explored through the network pharmacology technology and quality control indicators of the production process were optimized by cell anti-inflammatory experiments. Through these techno-logies, it would be more specific, scientific and effective to carry out process optimization of each link and multidimensional quality control of the whole process. The dosage and oral compliance for special patients(children) were explored, providing a reference for clinical pediatric medication of Pudilan Xiaoyan Oral Liquid. Simultaneously, it is helpful to expand the application market by developing Pudilan daily chemical products, and promote the traditional Chinese medicine products in terms of curative effect and daily life.
Related Concept Videos
Preclinical Development: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Bioavailability Enhancement: Drug Permeability Enhancement
Clinical Trials: Overview
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

